

COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P. Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).

Date: August 1<sup>st</sup> 2020 tel: +31 (0)10 7041470 Reference: - fax: +31 (0)10 7041022

Subject: ESHO strategy plan 2020-2025 e-mail: g.c.vanrhoon@erasmusmc.nl

The European Society for Hyperthermic Oncology (ESHO) is registered at the Dutch Chamber of Commerce, Amsterdam, The Netherlands under number KvK 40537174 and is recognized by the Dutch Ministry of Finance as Public Benefit Organisation" (Dutch: Algemeen Nut Beogende Instelling, ANBI), registration number 805406219 (RSIN/fiscal number).

The ESHO board consists of nine persons. Every year 3 members are replaced. Members of the 2020-2021 ESHO board are:

- 1. M.W. Kolff, The Netherlands
- 2. G. Multhoff, Germany
- 3. T. Samaras, Greece
- 4. G.C. van Rhoon, The Netherlands, president
- 5. J. Crezee, The Netherlands, secretary/treasurer
- 6. P. Ghadjar, Germany
- 7. U. Gaipl, Germany
- 8. B. Lindner, Poland
- 9. N.R. Datta, Switzerland

As stipulated below the Board members perform all activities for the ESHO board voluntarily, they receive no payment.

The objectives for which the Society is established are (see also the statutes elsewhere on the web-site):

- A. To carry out the following aims (hereinafter called "the primary objectives") namely, to promote for the public benefit, fundamental and applied research in physics, engineering, biological and clinical sciences relating to the use of hyperthermia in cancer therapy.
- B. To facilitate integration and exchange of information between different disciplines in the study of the biological effects of heat in the treatment of cancer either alone or combined with other cancer treatment modalities.

The next pages of this document provide ESHO's policy and workplans for the period of 2020 to 2025. The financial statement for 2019 is also provided at the end of this document.

### **EUROPEAN SOCIETY FOR HYPERTHERMIC ONCOLOGY (ESHO)**

www.ESHO.info

COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P. Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).

### ESHO policy document for 2020-2025.

In compliance with the objectives presented in detail in the Statutes of the European Society for Hyperthermic Oncology, the activities of the society for the five year period 2020-2025 will address the following items:

### Scientific Promotion

In 2021 ESHO will refrain from an annual scientific meeting. Instead ESHO will be responsible to organise the 13<sup>th</sup> International Conference on Hyperthermia in Oncology (ICHO). The ICHO is organised every 4 year under the auspices of the three major continental hyperthermia societies, i.e. ESHO, Society for Thermal Medicine (STM) and the Asian Society for Hyperthermic Oncology (ASHO). STM is the representative society for all types of treatments associated with thermal medicine (thermal ablation, hyperthermia, cryotherapy, long duration mild whole body) in the United States. The ASHO is the coordinating society of all Asian hyperthermia societies, like those active in Japan, Korea, India and China.

The most important objective of ICHO is to provide a worldwide platform where all researchers in hyperthermia can meet and exchange their scientific knowledge and clinical experience in hyperthermia.

The 13<sup>th</sup> ICHO is scheduled for October 6-9, 2021. On behalf of ESHO the ICHO 2021 will be organised by a team of Dutch ESHO members and will take place in Rotterdam, The Netherlands. Full details on the ICHO 2021 congress are available at <a href="https://www.icho2021.eu">www.icho2021.eu</a>.

- The next ESHO annual scientific meetings are scheduled to be in autumn 2022 in Gothenburg, Sweden; autumn 2023 in Cologne, Germany and autumn 2024 for which the location is still to be decided. Important issues for each scientific meeting are promotion of hyperthermia as an important clinical modality to enhance the effectiveness of radiotherapy and chemotherapy.
- To increase exchange scientific knowledge among the hyperthermia research community ESHO promotes their members to participate in the annual meetings of their sister organisations (ASHO,STM) as well as to participate in the annual meeting of international societies representing the pillars cancer treatment (radiotherapy, chemotherapy, surgery), i.e. societies such as ESTRO, ASTRO, ASCO, etc.
- In addition all ESHO members, but especially ESHO board members will actively promote hyperthermia by contributions (presentations, posters etc) at other relevant oncology and medical technology orientated scientific meetings.
- Finally, ESHO promotes publication of all scientific research in the International Journal of Hyperthermia, the official journal of the Society for Thermal Medicine, the European Society for Hyperthermic Oncology, and the Japanese Society of Hyperthermic Oncology. In addition, ESHO encourages publication of results of ground-breaking clinical studies in the highest ranking peer reviewed cancer journals.

### Exchange of knowledge

- Yearly three ESHO board members will be elected as the Public Relations committee. They will be responsible for the ESHO web-page and the ESHO newsletter.

COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P. Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).

- A new ESHO web-page (esho.info) has been introduced in 2019. The ESHO web-site provides information for a general and professional audience on hyperthermia in cancer treatment, ongoing clinical trials and medical/academical centers that provide evidence based hyperthermia treatments.
- The intention is to distribute an ESHO newsletter four times a year. The newsletter will be emailed to all ESHO members and others with an interest in hyperthermia. The newsletter will provide information on all recent and current activities of ESHO and associated sister organisations, literature reviews and summaries, active and upcoming clinical trials, introduce new hyperthermia centers etc.
- ESHO will continue to consider the International Journal of Hyperthermia as the only official society journal and promote its members to submit their scientific manuscripts to this journal.

### Society membership

- ESHO has members from all over Europe and the world. The society aims at having a good balance over the disciplines (medicine, biology, physics/engineering) involved in the clinical application of hyperthermia. Special attention will be given to ensure a well-balanced representation of members from across Europe. Cooperation with relevant associated societies, for instance high intensity ultrasound, will be pursued as well as close cooperation with European Union initiatives, such as Cost Actions or Innovative Training Networks, will be supported whenever possible by combining activities like annual meetings, workshop, educational training, etc.
- Companies can only become an ESHO member through a corporate membership. All companies active within the field of oncology will be offered a corporate membership to ESHO. The additional income of this activity will be used for the support of ESHO research activities.

#### Clinical research

- To further extend the acceptance of hyperthermia as an important treatment modality for cancer, undisputable clinical evidence from international, multi-institutional randomized trials is mandatory. To stimulate the implementation of new trials the ESHO clinical committee and the Atzelsberg Circle (contact: hyperthermie@uk-erlangen.de) will work closely together. The agenda of the meeting will be a combined responsibility and at each ESHO annual meeting a combined "clinical study" meeting will be organised the day before the annual meeting starts. This Atzelsberg Circle was originally an initiative of the German hyperthermia community and is presently a multi-disciplinary forum at which medical specialist of all medical discipline meet together with physicists and biologist to discuss new clinical trials.
- ESHO is also the authority to contact the various medical authorities in the European countries involved in the official registration and recognition of new modalities for cancer treatments.

### Education

- With the growing number of medical centres applying hyperthermia the development of a strong education program is an important goal. ESHO will continue to organize an educational day prior to the ESHO annual meeting and has the intention to organise additional separate ESHO schools on hyperthermia, for instance in connection to the ICHO 2021 but also to other relevant meetings.
- To stimulate young investigators to participate in the annual meetings ESHO will stimulate companies to sponsor Young Investigator Awards to honour an excellent scientific contribution, which may be presented as a travel award to facilitate participation in the ESHO annual meeting. The aim is equal distribution of awards in each discipline: medicine, biology, technology. The award level may vary between € 250-500 each and will come with an official ESHO certificate. For ease of financing each Award will mention in addition to the name of ESHO the name of the sponsoring company.

COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P. Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).


- ESHO will continue to grant one award in the range of € 1000 to € 3000 per annum to recognize special scientific and societal merits of a senior ESHO member. Here again the Award will mention in addition to ESHO the name of the sponsoring company.

### Fundraising

- The treasurer will be responsible for deciding on the level of the annual membership fee.
- The total amount of membership fees must cover at least all regular running costs of ESHO.
- From 2020 onward the ESHO membership fee will be collected by Conventus Congressmanagement & Marketing GmbH. Special fundraising companies, Cancer Charity foundations across Europe but also private Charity foundations will be contacted for providing financial support of implementation of the essential clinical trials. From the fundraising achieved ESHO will sponsor only scientific activities that are needed for the active implementation and scientific analysis of such trails.
- Special fundraising will aim at companies to secure funds for the various ESHO awards.

### Management of assets.

- ESHO will only have financial resources. It will not own any estate properties.
- All assets will only be used for the purposes stated in the statutes. ESHO-board members will not receive financial compensation for their efforts or participation to the annual meeting of ESHO. In exceptional cases ESHO will reimburse costs to the ESHO-board members for expenses they have made specifically for ESHO activities.
- The treasurer of ESHO will manage all ESHO assets as prescribed in the statutes, i.e. following a secure no/low risk policy.
- The accounts and the balance sheets of ESHO will be reported as prescribed by the statutes.
- ESHO will keep a financial reserve at the level of at least one annual meeting budget.
- In case of liquidation of ESHO all funds of ESHO will be donated to one or more scientific organisations active in the field of cancer research as stipulated in the statutes.



COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P. Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).

### Financial statement 2019



Management of The European Society For Hyperthermic Oncology Mr. G.C. van Rhoon Groene Hilledijk 301 3075 EA Rotterdam

Barendrecht, 11 May 2020

### Mons en Van Kan B.V.

Ebweg 16a Postbus 1150 2990 CA Barendrecht

Telefoon: (0180) 62 42 86 KvK nr.: 24170281 BTW nr.: 0071.88.973.B.01

IBAN : NL04 ABNA 0449 2032 20 BIC : ABNANL2A


#### COMPILATION REPORT

On the basis of information provided by the Association's management we have compiled the financial statements of The European Society For Hyperthermic Oncology, for the year 2019. The accuracy and completeness of the information provided and the financial statements based thereon are the responsibility of the Association's management. Our responsibility is to issue a compilation report on these financial statements.

Our procedures were limited primarily to gathering, processing, classifying and summarising financial information. These procedures do not provide the same level of assurance about whether the financial statements are free of material misstatements as that provided by an audit of review.

L.G. van Kan

Algemene voorwaarden gedeponeerd bij de Kamer van Koophandel




### EUROPEAN SOCIETY FOR HYPERTHERMIC ONCOLOGY (ESHO)

www.ESHO.info

COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P. Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).


European Society for Hypertherm	ic Oncology	
Financial statement year 2019		
	31-12-2019	31-12-2018
ASSETS	$\epsilon$	€
Current assets	3.000	
Cash at Banks	199.923	161.968
	202.923	161.968
LIABILITIES	€	$\epsilon$
Capital	94.740	78.785
Provisions		
Fund Heat Study Fund ESHO School activities ICHO Fund	87.183 10.000 3.000	62.183 10.000 3.000
	100.183	75.183
Current Liabilities		
Accrued expenses website	8.000	8.000
	***************************************	



COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P.

Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).

uropean Society for Hyperthermic Oncology		
inancial statement year 2019		
	2019	2018
ncome	$\epsilon$	$\epsilon$
r.G. Sennewald Medizintechnik, Heat Study SHO Pyrexar Award	25.000 3.000	60.000 3.000
SHO Young Investigator Award Iembership fees nnual meeting 2019	1.050 9.387 4.950	1.575 9.278
Annual meeting 2018 nterest Release reservation Fund Heat Study	3.272 58	154 28.669
	46.717	102.676
xpenses		
eat Study ublishing costs		88.669 2.454
SHO Pyrexar Award SHO Young Investigator Award	3.000 1.000	3,000 1,000 2,182
alary and social security expenses M. van Rhoon ecountant ankcharges	908 714	1.222 791
Office costs / various expenses Octation reservation Fund Heat Study	140 25.000	211
	30.762	99.529
otal running year	15.955	3.147



COUNCIL: G.C. van Rhoon, president (The Netherlands); J. Crezee, secretary general (The Netherlands); W. Kolff (The Netherlands), T. Samaras (Greece), G. Multhoff (Germany), P. Ghadjar (Germany), B. Lindner (Poland), N.R. Datta (Switzerland) and U. Gaipl (Germany).

European Society for Hyperthermic Oncology		
Financial statement year 2019		
Capital	$\epsilon$	
Balance 31 december 2018	78.785	
income less expenses 2019	15.955	
Balance 31 december 2019	94.740	